The Five Tests Every Woman Over 40 Should Ask Her Doctor For, and How to Ask for Them

Women who know which five tests to request, and the exact words to use, receive guideline-concordant cardiac screening at far higher rates than women who ask vaguely or wait to be offered. Cardiovascular disease kills roughly one in three American women, about 420,000 deaths a year, more than all cancers combined. The technology to catch it early exists. The orders just don’t get written.

The Gap Is Not Knowledge. It Is the Order Line.

Your doctor did not order these tests because nobody asked. Here is how to ask.

A 47-year-old marathon runner sat in my office with a printout of her annual physical. Total cholesterol 195. LDL 118. Glucose 94. “My doctor said everything looks great,” she told me. Her father had a heart attack at 52. I ordered an ApoB and an Lp(a). Her ApoB came back at 112 mg/dL, atherogenic. Her Lp(a) was at the 90th percentile. Both invisible on the panel she’d been handed. Both present in her arteries for years.

She did everything right. Her standard physical asked the wrong questions.

This is the recurring failure in female cardiac prevention. Not missing technology. Missing orders. Women are 20 to 30 percent less likely than men to receive guideline-recommended statin therapy at the same level of risk (Nanna 2019). The under-treatment starts with under-testing. And under-testing starts the moment a normal-looking lipid panel ends the conversation.

Women don’t die from what they have. Women die from what they hold. They hold high ApoB behind a normal LDL. They hold hyperinsulinemia behind a normal glucose. They hold an inherited Lp(a) behind a clean diet. The danger is silent and the test is simple, and the only missing step is the request.

So this article is a script. Five tests. The exact wording. And what to say when the answer is no.

The OARS Rule: How to Make a Request a Doctor Cannot Easily Refuse

Before the five tests, the method. I teach my patients a four-part structure for asking. I call it the OARS Rule, because it is what keeps you moving when the current pushes back.

• O, Own the reason. State why the test applies to you specifically. “Because my father had an early MI.”
• A, Anchor to a guideline. Name the document. Clinicians respond to citations, not feelings.
• R, Request the exact test. Say the test name. “ApoB,” not “better cholesterol testing.”
• S, Specify the follow-up. Ask what the result will change. “If it’s elevated, what do we do?”

A request built this way is precise, evidence-anchored, and decision-linked. Shared decision-making research shows that when women use specific wording for test requests, ordering rates and downstream statin initiation rise measurably (McNamara 2019). Vagueness gets deferred. Precision gets ordered.

Now the five.

Test One: ApoB, Not Just LDL

What to say: “I’d like an ApoB added to my lipid panel. My LDL cholesterol tells me the cholesterol mass, but ApoB tells me the particle count, and the particle count is what enters the artery wall. Through menopause my LDL can look normal while ApoB runs high.”

LDL cholesterol measures how much cholesterol is riding inside your particles. ApoB measures how many atherogenic particles you have, because every VLDL, IDL, LDL, and Lp(a) particle carries exactly one ApoB protein (Sniderman 2019). Each one of those particles can lodge in an arterial wall and seed a plaque. The count is the threat.

This matters most for women in their forties and fifties because of what estrogen loss does to lipid metabolism. After the final menstrual period, women develop higher triglycerides, smaller and denser LDL particles, and increased hepatic VLDL output (El Khoudary 2016). Small dense particles carry less cholesterol each. So you can have a normal LDL number and a high particle count at the same time. The panel reassures you. The arteries do not agree.

In the UK Biobank, with nearly 293,000 participants free of cardiovascular disease at baseline, ApoB showed a stronger and more linear association with incident cardiovascular disease than LDL or non-HDL cholesterol, in both women and men (Richardson 2023). In a meta-analysis of roughly 233,000 people, each standard-deviation rise in ApoB carried about a 43 percent higher relative risk of major cardiovascular events, even after adjusting for LDL (Marston 2022).

The honesty rating: ApoB as the superior atherogenic marker is well established. (Honesty: 5/Solid)

When your doctor says “your LDL is fine, you don’t need it”: Reply, “I understand my LDL is in range. ApoB measures something LDL cannot, the particle number. The 2022 ACC consensus pathway lists ApoB as a risk-enhancing factor, especially with high triglycerides or metabolic syndrome (Lloyd-Jones 2022). I’d like it once to refine my picture.” A single ApoB costs roughly 20 to 40 dollars out of pocket. The argument is not worth more than the test.

This is the same blind spot covered in the borderline cholesterol trap. If your LDL has ever been called “borderline,” your ApoB is the test that settles it.

Test Two: Fasting Insulin, Not Just Fasting Glucose

What to say: “I’d like a fasting insulin drawn with my glucose. My glucose can stay normal for years while my insulin climbs to keep it there, and that early insulin resistance is doing vascular damage I can’t see on a glucose number alone.”

Here is the physiology your glucose number hides. When muscle, liver, and fat resist insulin, the pancreas compensates by making more of it. That extra insulin keeps your fasting glucose looking normal, sometimes for a decade (Tabák 2012). By the time glucose finally drifts past 100 mg/dL, beta-cell stress and arterial damage are already underway. Glucose is the late alarm. Insulin is the early one.

Hyperinsulinemia is not benign waiting. It drives endothelial dysfunction, raises sympathetic tone, retains sodium and raises blood pressure, and produces the exact atherogenic lipid pattern, high triglycerides, low HDL, small dense LDL, that I described in Test One. These problems compound.

The data in women are specific. In the Women’s Health Study, with more than 27,000 female health professionals, women in the highest fasting insulin quartile had roughly double the risk of incident cardiovascular disease compared to the lowest, even with fasting glucose in the normal range (Pradhan 2004). The risk lived in the insulin, not the glucose.

Certain women carry this risk far more often: a history of gestational diabetes, polycystic ovary syndrome, or central adiposity even at a normal BMI (Mendelson 2018). If you have any of those, fasting insulin is not optional curiosity. It is the test that explains the fatigue, the mild hypertension, and the family history of diabetes that the glucose number keeps calling “fine.”

The honesty rating: Fasting insulin as an early marker of insulin resistance is mechanistically sound and supported by cohort data. It is not yet in universal screening guidelines. (Honesty: 4/Promising)

When your doctor says “your glucose is normal, that’s what matters”: Reply, “Glucose is normal because my insulin is working overtime to keep it there. I’d like to see the insulin so we catch resistance before it becomes prediabetes. Given my history of [gestational diabetes / PCOS / family diabetes], I think one fasting insulin is reasonable.” Pair it with an HbA1c if you want a fuller metabolic picture.

Test Three: Coronary Artery Calcium Score

What to say: “I’d like a coronary artery calcium score. I’m over 40 with [family history / hypertension / abnormal lipids / prior preeclampsia], and I want to know whether plaque is already present before we decide on prevention. A zero could de-risk me. A high score would change what we do.”

A CAC score is a low-dose CT that counts calcified plaque in your coronary arteries. Calcification is the artery’s healing response to atherosclerosis, so its presence means the disease has been active for years (Budoff 2018). It is not a prediction. It is a photograph of what is already there.

The numbers are decisive. In MESA, women with any calcium, a score above zero, had three to six times the coronary heart disease risk of women with a score of zero, even after adjusting for traditional risk factors (Budoff 2018). CAC reclassifies risk beyond the pooled cohort equations, which is exactly where women in the borderline and intermediate range, 5 to 19.9 percent ten-year risk, are most often misjudged.

There is a female caveat worth knowing. Women tend to have lower CAC scores than men at a given age because they are more prone to non-calcified plaque, microvascular dysfunction, and plaque erosion rather than rupture (Shaw 2015). A CAC of zero in a symptomatic woman does not erase all risk. But in the asymptomatic woman deciding whether to start a statin, CAC is unusually powerful. The 2019 ACC/AHA prevention guideline calls it reasonable, Class IIa, for adults 40 to 75 in the borderline-to-intermediate range, precisely to guide that decision (Arnett 2019).

The honesty rating: CAC for risk refinement in midlife women is guideline-endorsed and strongly evidence-based. (Honesty: 5/Solid)

The cost question: A CAC score runs 100 to 400 dollars out of pocket and is often not covered. It is one of the highest-yield dollars you can spend on your heart. A score of zero may justifiably let a hesitant woman defer a statin. A score above 100, or above the 75th percentile for your age and sex, makes the case for treatment in a way no risk calculator can. It turns argument into evidence.

If you are still unsure whether you need a specialist for this conversation, this guide on when a woman needs a cardiologist draws the line.

Test Four: Lp(a), Once in Your Life

What to say: “I’d like a one-time Lp(a) test. It’s genetically inherited, it doesn’t move with diet or exercise, and it can explain heart attack risk in people who otherwise look low-risk. About one in five people carries an elevated level. I want to know if I’m one of them.”

Lp(a) is an LDL-like particle with an extra protein, apolipoprotein(a), bolted on. That structure makes it triply dangerous: it is atherogenic like LDL, it carries oxidized phospholipids that inflame the endothelium, and its resemblance to plasminogen makes it pro-thrombotic (Tsimikas 2018). It builds plaque and it favors clots.

Its defining feature is that it is set by your genes. Lp(a) is stable from about age five and does not meaningfully respond to diet, exercise, or most cholesterol drugs (Tsimikas 2018). This is why you test it once. It also explains the most frustrating cases in my practice: the woman with an excellent diet, a normal BMI, good standard cholesterol, and a premature heart attack or an unexpected CAC score. Lp(a) is often the missing variable.

Roughly 20 to 25 percent of people carry an elevated Lp(a), at or above 50 mg/dL or 125 nmol/L, with prevalence similar or slightly higher in women (Tsimikas 2018). When high Lp(a) and high LDL occur together, the myocardial infarction risk multiplies rather than adds. And elevated Lp(a) also predicts calcific aortic stenosis, a valve disease that strikes older women disproportionately and is frequently caught late.

The honesty rating: Lp(a) as an inherited, once-in-a-lifetime risk marker is endorsed by both the 2022 ACC pathway and the 2021 ESC guidelines (Visseren 2021). The drugs to lower it directly are still in trials. The knowledge is actionable now because it changes how aggressively we treat everything else. (Honesty: 4/Promising)

When your doctor says “there’s no drug for it, so why test”: Reply, “Even if I can’t lower Lp(a) directly, knowing it’s high changes my LDL and ApoB targets and whether I should start treatment now rather than later. The ESC and ACC both recommend measuring it once. I’d like that one measurement.” A high Lp(a) is also information your children inherit. It is a family fact, not just yours.

Test Five: A Menopause-Specific Cardiovascular Risk Assessment

What to say: “I’m in [perimenopause / postmenopause]. I’d like a cardiovascular risk assessment that accounts for my menopausal status, not just my age. The transition itself shifts my lipids and blood pressure beyond what aging alone explains, and I want my prevention to reflect that.”

The menopausal transition is a cardiovascular pivot, not a gentle slope. The SWAN cohort showed that the years around the final menstrual period drive sharp, unfavorable changes independent of chronological aging: total cholesterol rising roughly 10 to 15 mg/dL, LDL climbing about 10 mg/dL, ApoB rising, blood pressure increasing, and fat redistributing centrally (El Khoudary 2016). A risk calculator built on age alone misses the inflection.

I call the highest-risk stretch the Perimenopause Vascular Inflection Window, the roughly five years on either side of the final period. This is when ApoB, fasting insulin, and CAC deliver the most information, because the changes are happening fast and the standard physical is calibrated for the woman you were five years ago, not the one you are becoming. A menopause-specific assessment means your clinician asks about cycle changes, hot flashes, sleep disruption, and pregnancy history, including preeclampsia and gestational diabetes, all of which carry independent cardiovascular weight that a generic intake skips.

A history of preeclampsia roughly doubles later cardiovascular risk. It belongs in your cardiac assessment, not just your obstetric record. So does early menopause before 45, which accelerates the same risk shift.

The honesty rating: The menopause transition as an independent driver of cardiovascular risk shift is well documented in longitudinal cohorts. (Honesty: 5/Solid)

This is the assessment most physicals skip entirely, and it is the subject of the dedicated perimenopause cardiac risk guide. If your physical has never asked about your pregnancies or your menopausal timeline, it has been missing the tests that matter.

The Five Numbers You Walk Out With

Put together, these five requests give you a real baseline: your ApoB particle count, your fasting insulin, your calcium score, your once-in-a-lifetime Lp(a), and a risk picture anchored to your menopausal stage rather than your birth year. These are the five numbers that define your cardiac baseline, and the difference between knowing them and not knowing them is often the difference between prevention and a first event.

The total cost, if you pay entirely out of pocket and nothing is covered, runs roughly 250 to 500 dollars for all five, with the CAC score being the largest single line. Much of it is often covered when ordered with the right reasoning. None of it requires anything more than a written order, and the order requires nothing more than the request.

The anti-passive rule applies here without exception. Do not leave your appointment having “mentioned” these tests. Leave with orders or a written explanation of why each was declined. A clinician who declines in writing has to justify it. A patient who only mentioned it has nothing to follow up on.

Your Next Step

Take the /women cardiac risk assessment before your next appointment. It will generate a personalized list of which of these five tests apply most urgently to you, based on your family history, menopausal stage, and prior numbers, and it produces a one-page printout with the exact request language you can hand your physician. Walk in with the printout. Walk out with the orders.

The knowledge gap is the action gap. You just closed the knowledge gap. Now close the action gap.

Frequently Asked Questions

What five tests should every woman over 40 ask her doctor for?

ApoB instead of relying on a standard lipid panel alone, fasting insulin alongside fasting glucose, a coronary artery calcium score if you are 40 or older with any risk factors, a one-time Lp(a) measurement, and a menopause-specific cardiovascular risk assessment. These five close the gap between a normal-looking physical and your actual arterial reality. Standard care orders none of them by default, which is why women must request them by name. Each costs little, each adds information the routine panel cannot, and together they convert a vague sense of “I feel healthy” into a measured baseline you can act on. The total out-of-pocket cost for all five typically runs 250 to 500 dollars.

How do I ask my doctor for ApoB without being dismissed?

Use precise language: “I’d like an ApoB added to my lipid panel because my LDL cholesterol may not reflect my actual particle count, especially through menopause.” Anchor it to the 2022 ACC consensus pathway, which lists ApoB as a risk-enhancing marker, particularly with high triglycerides or metabolic syndrome. Frame it as risk refinement, not anxiety. Specificity signals you have done the reading, and shared decision-making research confirms clinicians order more when patients request exactly. If your doctor says your LDL is fine, reply that ApoB measures particle number, which LDL cannot, and that you want it once to refine your picture. A single ApoB costs roughly 20 to 40 dollars.

My fasting glucose is normal. Why should I still ask for a fasting insulin test?

Fasting glucose stays normal for years while your pancreas overproduces insulin to keep it there. That compensation, hyperinsulinemia, damages arteries before glucose ever rises. In the Women’s Health Study, women in the highest fasting insulin quartile had roughly double the cardiovascular risk despite normal glucose. Insulin resistance can precede impaired fasting glucose by a decade, particularly after gestational diabetes or PCOS, or with central adiposity at a normal BMI. The extra insulin drives endothelial dysfunction, raises blood pressure through sodium retention, and produces an atherogenic lipid pattern. A normal glucose is the late alarm. Fasting insulin is the early one, and catching resistance early is where prevention still works easily.

Should I get a coronary calcium score at 45 if I feel healthy?

If you have any risk factor, family history, hypertension, abnormal lipids, or prior preeclampsia, yes. A CAC score is a low-dose CT that shows whether calcified plaque is already present in your coronary arteries, meaning at